Seattle Genetics, Inc. operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Seattle Genetics with three other
companies in this sector in the United States:
sales of $642.99 million
of which 66%
Acorda Therapeutics, Inc.
of which 98%
was Net product revenues), and
of which 61%
was SCIT/SLIT drops).
During the year ended December of 2018, sales at
Seattle Genetics were $654.70 million.
increase of 35.8%
versus 2017, when the company's sales were $482.25 million.
This was the fifth consecutive year of sales increases at Seattle Genetics
(and since 2013, sales have increased a total of 143%).